KIMS reports Q2 FY27 growth with 14.0% QoQ revenue increase

Capex intensity: cash flows from investing are strongly negative (–₹1,452 Cr vs –₹1,116 Cr prior), signalling heavy near-term investment and cash absorption for new hospitals/CWIP (CWIP ₹606 Cr). Asset base: fixed assets ~₹5,710 Cr with CWIP shows an asset-heavy expansion; incremental beds materially increase capacity and future revenue potential once utilization ramps. Profitability signal: ROCE has declined (latest ~10% from ~15%), indicating current returns are under pressure — new capacity must achieve strong utilisation to restore returns. Valuation sensitivity: market cap ~₹31,104 Cr and high P/E (~149) imply the stock already prices future growth; execution shortfalls or slow ramp-up would hurt investor returns. High-value services: addition of oncology, NICU and mother/child blocks increases potential ARPOB and margin mix if case mix and utilisation rise as expected.